Blue Dot News

One story a day from the frontier of human knowledge.

Medicine ·

Medicine

We Learned to Edit a Single Misspelled Word in the Book of Life

A therapy built from a bacterial defense system has been used to correct the genetic error behind sickle cell disease — the first medicine of its kind to reach patients.

Illustration: Blue Dot News

1 min read

Your body runs on an instruction book written in three billion chemical letters. In sickle cell disease, just one of those letters is wrong — and that single mistake is enough to twist red blood cells into rigid crescents that clog the bloodstream and cause waves of severe pain.

Scientists found a way to fix it using a tool that bacteria invented to fight off viruses, called CRISPR. Working like precise molecular scissors, it can be sent to an exact spot in a person's DNA. Doctors take a patient's own cells, switch a helpful backup gene back on, and return the cells to the body. In the studies, most patients stopped having the pain crises that had shaped their whole lives.

It is the first approved medicine that works by rewriting human DNA on purpose — and it will not be the last. We have learned to find one wrong word in a book of three billion, and to set it right. With that power comes a responsibility to use it wisely and fairly.

The people behind the work

  • Emmanuelle Charpentier & Jennifer Doudna

    Discovered CRISPR-Cas9 gene editing (Nobel Prize, 2020)

    Max Planck Unit / University of California, Berkeley

  • Stuart Orkin

    Identified the genetic switch the therapy targets

    Boston Children's Hospital / Harvard Medical School

Source: U.S. Food and Drug Administration

Sources & Verification

Every statement in this story is drawn from the facts below. Each is linked to a primary or reputable source — follow any citation to check it for yourself.

  1. On 8 December 2023, the FDA approved Casgevy (exagamglogene autotemcel) — the first medicine in the US to treat a genetic disease with CRISPR gene editing — for sickle cell disease in patients aged 12 and older. STAT — In historic decision, FDA approves a CRISPR-based medicine for sickle cell disease
  2. Casgevy uses CRISPR-Cas9 to edit the BCL11A enhancer in a patient's own blood stem cells, switching fetal hemoglobin back on to compensate for the faulty adult hemoglobin. Vertex & CRISPR Therapeutics — US FDA Approval of CASGEVY
  3. CRISPR-Cas9 gene editing was developed by Emmanuelle Charpentier and Jennifer Doudna, who received the 2020 Nobel Prize in Chemistry for it. The Nobel Prize in Chemistry 2020
  4. The human genome contains about 3 billion base pairs ("letters"); sickle cell disease is caused by a single change in the gene for hemoglobin. National Human Genome Research Institute (genome.gov)

This is an illustrative sample written to demonstrate the design and voice of Blue Dot News. The underlying science is real; the article is for preview purposes.

← All stories